

Luiz SÃ©rgio F De Carvalho

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/701062/publications.pdf>

Version: 2024-02-01

60
papers

873
citations

623734

14
h-index

501196

28
g-index

65
all docs

65
docs citations

65
times ranked

1869
citing authors

#	ARTICLE	IF	CITATIONS
1	Orchestrating a ceramide-phosphatidylcholine cardiovascular risk score: it ain't over 'til the fat layer sings. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 892-894.	1.8	2
2	Rationale and design of the Brazilian diabetes study: a prospective cohort of type 2 diabetes. <i>Current Medical Research and Opinion</i> , 2022, 38, 523-529.	1.9	3
3	Compliance with Cardiovascular Prevention Guidelines in Type 2 Diabetes Individuals in a Middle-Income Region: A Cross-Sectional Analysis. <i>Diagnostics</i> , 2022, 12, 814.	2.6	1
4	Increased particle size of triacylglycerol-enriched remnant lipoproteins, but not their plasma concentration or lipid content, augments risk prediction of incident type 2 diabetes. <i>Diabetologia</i> , 2021, 64, 385-396.	6.3	15
5	O Escore Gensini e a Carga Tromb�tica Adicionam Valor Preditivo ao Escore SYNTAX na Detec�o de No-Reflow ap�s Infarto do Mioc�rdio. <i>Arquivos Brasileiros De Cardiologia</i> , 2021, 116, 466-472.	0.8	4
6	Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial. <i>Cardiovascular Diabetology</i> , 2021, 20, 74.	6.8	44
7	Intra-operative esmolol and pain following mastectomy. <i>European Journal of Anaesthesiology</i> , 2021, 38, 735-743.	1.7	6
8	Cardiovascular safety of naltrexone and bupropion therapy: Systematic review and meta�nalysis. <i>Obesity Reviews</i> , 2021, 22, e13224.	6.5	10
9	Dapagliflozin increases the lean-to total mass ratio in type 2 diabetes mellitus. <i>Nutrition and Diabetes</i> , 2021, 11, 17.	3.2	8
10	Glucose-lowering Drugs and Hospitalization for Heart Failure: A Systematic Review and Additive-effects Network Meta-analysis With More Than 500 000 Patient-years. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 3060-3067.	3.6	7
11	Defective Allele of the Neuronal Nitric Oxide Synthase Gene Increases Insulin Resistance During Acute Phase of Myocardial Infarction. <i>International Journal of General Medicine</i> , 2021, Volume 14, 3669-3676.	1.8	0
12	O Impacto da Educa�o na Mortalidade por Todas as Causas ap�s Infarto do Mioc�rdio com Supradesnivelamento do Segmento ST (IAMCSST): Resultados do Bras�lia Heart Study. <i>Arquivos Brasileiros De Cardiologia</i> , 2021, 117, 5-12.	0.8	2
13	The impact of low income on long-term mortality of myocardial infarction patients: results from the Brazilian Heart Study. <i>Current Medical Research and Opinion</i> , 2021, 37, 1689-1695.	1.9	0
14	Dapagliflozin increases retinal thickness in type 2 diabetic patients as compared with glibenclamide: A randomized controlled trial. <i>Diabetes and Metabolism</i> , 2021, 47, 101280.	2.9	6
15	Dapagliflozin reduces adiposity and increases adiponectin in patients with type 2 diabetes and atherosclerotic disease at short-term: an active-controlled randomised trial. <i>Diabetes and Metabolism</i> , 2021, 48, 101304.	2.9	1
16	Lower bone mass is associated with subclinical atherosclerosis, endothelial dysfunction and carotid thickness in the very elderly. <i>Atherosclerosis</i> , 2020, 292, 70-74.	0.8	10
17	Excess weight mediates changes in HDL pool that reduce cholesterol efflux capacity and increase antioxidant activity. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 254-264.	2.6	9
18	Machine Learning Improves the Identification of Individuals With Higher Morbidity and Avoidable Health Costs After Acute Coronary Syndromes. <i>Value in Health</i> , 2020, 23, 1570-1579.	0.3	14

#	ARTICLE	IF	CITATIONS
19	Rationale and design of the expanded combination of evolocumab plus empagliflozin in diabetes: EXCEED-BHS3 trial. <i>Therapeutic Advances in Chronic Disease</i> , 2020, 11, 204062232095924.	2.5	10
20	Letter to the Editor: "Cardiovascular Effects of Pioglitazone or Sulfonylureas According to Pretreatment Risk: Moving Toward Personalized Care" <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e907-e908.	3.6	0
21	Synergistic effect of the association between lidocaine and magnesium sulfate on peri-operative pain after mastectomy. <i>European Journal of Anaesthesiology</i> , 2020, 37, 224-234.	1.7	14
22	Statin Use in the Early Phase of ST-Segment Elevation Myocardial Infarction Is Associated With Decreased QTc Dispersion. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2020, 25, 226-231.	2.0	1
23	1480-P: Increased Particle Size of Triglyceride Remnant Lipoproteins, but Not Plasma Concentration or Lipid Content, Boost Risk Prediction of Incident Type 2 Diabetes. <i>Diabetes</i> , 2020, 69, .	0.6	0
24	Statin Short-term Inhibition of Insulin Sensitivity and Secretion During Acute Phase of ST-Elevation Myocardial Infarction. <i>Scientific Reports</i> , 2019, 9, 16401.	3.3	2
25	Reciprocal Multifaceted Interaction Between HDL (High-Density Lipoprotein) and Myocardial Infarction. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 1550-1564.	2.4	21
26	Omega-3 intake is associated with attenuated inflammatory response and cardiac remodeling after myocardial infarction. <i>Nutrition Journal</i> , 2019, 18, 29.	3.4	10
27	Intensive treatment of hyperglycemia in the acute phase of myocardial infarction: the tenuous balance between effectiveness and safety " a systematic review and meta-analysis of randomized clinical trials. <i>Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira</i> , 2019, 65, 24-32.	0.7	4
28	Prevalence, treatment, and control of dyslipidemia in diabetic participants of two brazilian cohorts: a place far from heaven. <i>Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira</i> , 2019, 65, 3-8.	0.7	2
29	Inhibition of the sodium-glucose co-transporter 2 in the elderly: clinical and mechanistic insights into safety and efficacy. <i>Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira</i> , 2019, 65, 70-86.	0.7	15
30	HDL-Targeted Therapies During Myocardial Infarction. <i>Cardiovascular Drugs and Therapy</i> , 2019, 33, 371-381.	2.6	14
31	Adverse interaction between HDL and the mass of myocardial infarction. <i>Atherosclerosis</i> , 2019, 281, 9-16.	0.8	8
32	Change of BNP between admission and discharge after ST-elevation myocardial infarction (Killip I) improves risk prediction of heart failure, death, and recurrent myocardial infarction compared to single isolated measurement in addition to the GRACE score. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 643-651.	1.0	21
33	Updated Cardiovascular Prevention Guideline of the Brazilian Society of Cardiology - 2019. <i>Arquivos Brasileiros De Cardiologia</i> , 2019, 113, 787-891.	0.8	102
34	Total cholesterol and the risk of stroke: A double-edged sword or a blunt knife?. <i>Atherosclerosis</i> , 2018, 270, 191-192.	0.8	3
35	Relevance of AND-ASPEN criteria of malnutrition to predict hospital mortality in critically ill patients: A prospective study. <i>Journal of Critical Care</i> , 2018, 44, 398-403.	2.2	29
36	Adverse outcome has a U-shaped relation with acute phase change in insulin sensitivity after ST-Elevation Myocardial Infarction. <i>International Journal of Cardiology</i> , 2018, 254, 16-22.	1.7	1

#	ARTICLE	IF	CITATIONS
37	Adiponectin concentration data improve the estimation of atherosclerotic risk in normal and in overweight subjects. <i>Clinical Endocrinology</i> , 2018, 88, 388-396.	2.4	4
38	Response to Comment on de Carvalho et al. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years. <i>Diabetes Care</i> 2018;41:364-367. <i>Diabetes Care</i> , 2018, 41, e70-e71.	8.6	1
39	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years. <i>Diabetes Care</i> , 2018, 41, 364-367.	8.6	88
40	GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data. <i>Cardiovascular Diabetology</i> , 2018, 17, 157.	6.8	97
41	Cystatin C as a Candidate Biomarker of Cardiovascular Outcomes: Too Near, but too Far from Reality. <i>Arquivos Brasileiros De Cardiologia</i> , 2018, 111, 808-809.	0.8	0
42	Smoking-epigenetics interaction: What do microRNAs tell us about susceptibility to atherosclerotic disease in smokers?. <i>Atherosclerosis</i> , 2017, 263, 309-310.	0.8	2
43	Can microRNAs improve prediction of abdominal aortic aneurysm growth?. <i>Atherosclerosis</i> , 2017, 256, 131-133.	0.8	3
44	Statin-associated muscle symptoms: position paper from the Luso-Latin American Consortium. <i>Current Medical Research and Opinion</i> , 2017, 33, 239-251.	1.9	18
45	TCF7L2 polymorphism is associated with low nitric oxide release, endothelial dysfunction and enhanced inflammatory response after myocardial infarction. <i>BBA Clinical</i> , 2016, 5, 159-165.	4.1	2
46	Monthly PCSK9 inhibitors: The CHOICE for prolonged duration of effect. <i>Atherosclerosis</i> , 2016, 254, 300-302.	0.8	1
47	Endothelial nitric oxide synthase genotypes modulate peripheral vasodilatory properties after myocardial infarction. <i>Gene</i> , 2015, 568, 165-169.	2.2	7
48	Vitamin D for the prevention of cardiovascular disease: Are we ready for that?. <i>Atherosclerosis</i> , 2015, 241, 729-740.	0.8	60
49	Glycosylated hemoglobin is associated with decreased endothelial function, high inflammatory response, and adverse clinical outcome in non-diabetic STEMI patients. <i>Atherosclerosis</i> , 2015, 243, 124-130.	0.8	17
50	HDL levels and oxidizability during myocardial infarction are associated with reduced endothelial-mediated vasodilation and nitric oxide bioavailability. <i>Atherosclerosis</i> , 2014, 237, 840-846.	0.8	25
51	Elevated CETP activity during acute phase of myocardial infarction is independently associated with endothelial dysfunction and adverse clinical outcome. <i>Atherosclerosis</i> , 2014, 237, 777-783.	0.8	22
52	Validation of surrogate indexes of insulin sensitivity in acute phase of myocardial infarction based on euglycemic-hyperinsulinemic clamp. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2014, 306, E399-E403.	3.5	15
53	High-density lipoprotein levels are strongly associated with the recovery rate of insulin sensitivity during the acute phase of myocardial infarction: A study by euglycemic hyperinsulinemic clamp. <i>Journal of Clinical Lipidology</i> , 2013, 7, 24-28.	1.5	4
54	Pericardial fat volume measured by non-contrast tomography improves risk prediction of subclinical coronary artery disease estimated by coronary artery calcium score and Framingham risk score. <i>European Heart Journal</i> , 2013, 34, P3137-P3137.	2.2	0

#	ARTICLE	IF	CITATIONS
55	High cholesteryl ester transfer protein (CETP) activity in acute phase of myocardial infarction predicts short-term mortality by inducing endothelial dysfunction and reduced microvascular perfusion. <i>European Heart Journal</i> , 2013, 34, P475-P475.	2.2	1
56	Validation of HOMA2S in acute phase of myocardial infarction, based on euglycemic-hyperinsulinemic clamp. <i>European Heart Journal</i> , 2013, 34, P1272-P1272.	2.2	0
57	High plasma HDL-C attenuates stress hyperglycemia during acute phase of myocardial infarction. <i>Atherosclerosis</i> , 2012, 220, 231-236.	0.8	9
58	Atherosclerotic disease in octogenarians: A challenge for science and clinical practice. <i>Atherosclerosis</i> , 2012, 225, 281-289.	0.8	29
59	The I405V and Taq1B polymorphisms of the CETP gene differentially affect sub-clinical carotid atherosclerosis. <i>Lipids in Health and Disease</i> , 2012, 11, 130.	3.0	4
60	Rebound inflammatory response during the acute phase of myocardial infarction after simvastatin withdrawal. <i>Atherosclerosis</i> , 2009, 207, 191-194.	0.8	61